123I-β-methyl-iodophenyl-pentadecanoic acid myocardial scintigraphy in diabetic patients without overt ischemic heart disease

K. Shinmura, M. Tani, Y. Suganuma, H. Hasegawa, M. Kawamura, Y. Nakamura, J. Hashimoto, A. Kubo

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Fatty acid metabolism in the myocardium is affected by metabolic disorders such as diabetes mellitus. We evaluated 123I-,β-methyl-iodophenyl- pentadecanoic acid (BMIPP) myocardial scintigraphy in 15 diabetes mellitus patients without overt coronary heart disease. Patients with overt coronary heart disease were excluded by careful history taking, resting electrocardiography, treadmill exercise testing, echocardiography and resting 201TI scintigraphy. Patients with remarkably impaired left ventricular (LV) systolic function (%FS<30%) were also excluded. BMIPP uptake scores as the ratio of heart/mediastinum (H/M) and liver/mediastinum (L/M) at 20 minutes after injection were analyzed and compared with clinical profile, serum parameters, and LV parameters obtained from echocardiography. Five of the 15 patients showed abnormal BMIPP images; two patients showed a decreased uptake in the inferior segments, while three showed a diffuse decrease in BMIPP uptake. Body mass index (BMI), fasting blood sugar (FBS), HbAIC, IRI, and LV end-diastolic diameter (LVEDD) were higher in these five patients with abnormal BMIPP findings (abnormal BMIPP group vs normal BMIPP group, BMI: 29 vs 23 kg/m2, p< 0.05; FBS; 178 vs 114 mg/dl, p<0.01; HbAIC; 7.6 vs 6.2%, p<0.01; IRI: 18.5 vs 9.5 μU/ml, p< 0.01; LVEDD: 52 vs 44 mm, p<0.05). 123I-metaiodobenzyl-guanidine (MIBG) scintigraphy in the five patients with abnormal BMIPP uptake showed more severe defects than in the 10 patients with normal BMIPP imaging. BMIPP scintigraphy demonstrated a significant correlation between H/M and L/M by BMIPP (r = 0.74, p<0.01). Furthermore, correlation between H/M by BMIPP scintigraphy and clinical parameters (BMI, systolic blood pressure, FBS, HbAIC, IRI) were found, suggesting that diabetes mellitus patients without over coronary heart disease show abnormal BMIPP imaging when their general glucose utility and 123I-MIBG uptake are severely impaired (progression of insulin resistance and sympathetic nerve involvement). BMIPP scintigraphy may be useful in investigating the pathogenesis and subclinical abnormality of diabetic heart.

Original languageEnglish
Pages (from-to)23-32
Number of pages10
JournalJournal of Cardiology
Volume26
Issue number1
Publication statusPublished - 1995

Fingerprint

Myocardial Perfusion Imaging
Myocardial Ischemia
Mediastinum
Radionuclide Imaging
Coronary Disease
Blood Glucose
Fasting
Diabetes Mellitus
Body Mass Index
Guanidine
pentadecanoic acid
iodofiltic acid
Echocardiography
Blood Pressure
Congenital Heart Defects
Liver
Left Ventricular Function
Insulin Resistance

Keywords

  • I-MIBG)
  • diabetes mellitus
  • fatty acid (metabolism)
  • glucose (metabolism)
  • radioisotopes (I-BMIPP

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Shinmura, K., Tani, M., Suganuma, Y., Hasegawa, H., Kawamura, M., Nakamura, Y., ... Kubo, A. (1995). 123I-β-methyl-iodophenyl-pentadecanoic acid myocardial scintigraphy in diabetic patients without overt ischemic heart disease. Journal of Cardiology, 26(1), 23-32.

123I-β-methyl-iodophenyl-pentadecanoic acid myocardial scintigraphy in diabetic patients without overt ischemic heart disease. / Shinmura, K.; Tani, M.; Suganuma, Y.; Hasegawa, H.; Kawamura, M.; Nakamura, Y.; Hashimoto, J.; Kubo, A.

In: Journal of Cardiology, Vol. 26, No. 1, 1995, p. 23-32.

Research output: Contribution to journalArticle

Shinmura, K, Tani, M, Suganuma, Y, Hasegawa, H, Kawamura, M, Nakamura, Y, Hashimoto, J & Kubo, A 1995, '123I-β-methyl-iodophenyl-pentadecanoic acid myocardial scintigraphy in diabetic patients without overt ischemic heart disease', Journal of Cardiology, vol. 26, no. 1, pp. 23-32.
Shinmura, K. ; Tani, M. ; Suganuma, Y. ; Hasegawa, H. ; Kawamura, M. ; Nakamura, Y. ; Hashimoto, J. ; Kubo, A. / 123I-β-methyl-iodophenyl-pentadecanoic acid myocardial scintigraphy in diabetic patients without overt ischemic heart disease. In: Journal of Cardiology. 1995 ; Vol. 26, No. 1. pp. 23-32.
@article{d7af1801f4644cb19ce2dd79898b8954,
title = "123I-β-methyl-iodophenyl-pentadecanoic acid myocardial scintigraphy in diabetic patients without overt ischemic heart disease",
abstract = "Fatty acid metabolism in the myocardium is affected by metabolic disorders such as diabetes mellitus. We evaluated 123I-,β-methyl-iodophenyl- pentadecanoic acid (BMIPP) myocardial scintigraphy in 15 diabetes mellitus patients without overt coronary heart disease. Patients with overt coronary heart disease were excluded by careful history taking, resting electrocardiography, treadmill exercise testing, echocardiography and resting 201TI scintigraphy. Patients with remarkably impaired left ventricular (LV) systolic function ({\%}FS<30{\%}) were also excluded. BMIPP uptake scores as the ratio of heart/mediastinum (H/M) and liver/mediastinum (L/M) at 20 minutes after injection were analyzed and compared with clinical profile, serum parameters, and LV parameters obtained from echocardiography. Five of the 15 patients showed abnormal BMIPP images; two patients showed a decreased uptake in the inferior segments, while three showed a diffuse decrease in BMIPP uptake. Body mass index (BMI), fasting blood sugar (FBS), HbAIC, IRI, and LV end-diastolic diameter (LVEDD) were higher in these five patients with abnormal BMIPP findings (abnormal BMIPP group vs normal BMIPP group, BMI: 29 vs 23 kg/m2, p< 0.05; FBS; 178 vs 114 mg/dl, p<0.01; HbAIC; 7.6 vs 6.2{\%}, p<0.01; IRI: 18.5 vs 9.5 μU/ml, p< 0.01; LVEDD: 52 vs 44 mm, p<0.05). 123I-metaiodobenzyl-guanidine (MIBG) scintigraphy in the five patients with abnormal BMIPP uptake showed more severe defects than in the 10 patients with normal BMIPP imaging. BMIPP scintigraphy demonstrated a significant correlation between H/M and L/M by BMIPP (r = 0.74, p<0.01). Furthermore, correlation between H/M by BMIPP scintigraphy and clinical parameters (BMI, systolic blood pressure, FBS, HbAIC, IRI) were found, suggesting that diabetes mellitus patients without over coronary heart disease show abnormal BMIPP imaging when their general glucose utility and 123I-MIBG uptake are severely impaired (progression of insulin resistance and sympathetic nerve involvement). BMIPP scintigraphy may be useful in investigating the pathogenesis and subclinical abnormality of diabetic heart.",
keywords = "I-MIBG), diabetes mellitus, fatty acid (metabolism), glucose (metabolism), radioisotopes (I-BMIPP",
author = "K. Shinmura and M. Tani and Y. Suganuma and H. Hasegawa and M. Kawamura and Y. Nakamura and J. Hashimoto and A. Kubo",
year = "1995",
language = "English",
volume = "26",
pages = "23--32",
journal = "Journal of cardiography. Supplement",
issn = "0914-5087",
publisher = "Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)",
number = "1",

}

TY - JOUR

T1 - 123I-β-methyl-iodophenyl-pentadecanoic acid myocardial scintigraphy in diabetic patients without overt ischemic heart disease

AU - Shinmura, K.

AU - Tani, M.

AU - Suganuma, Y.

AU - Hasegawa, H.

AU - Kawamura, M.

AU - Nakamura, Y.

AU - Hashimoto, J.

AU - Kubo, A.

PY - 1995

Y1 - 1995

N2 - Fatty acid metabolism in the myocardium is affected by metabolic disorders such as diabetes mellitus. We evaluated 123I-,β-methyl-iodophenyl- pentadecanoic acid (BMIPP) myocardial scintigraphy in 15 diabetes mellitus patients without overt coronary heart disease. Patients with overt coronary heart disease were excluded by careful history taking, resting electrocardiography, treadmill exercise testing, echocardiography and resting 201TI scintigraphy. Patients with remarkably impaired left ventricular (LV) systolic function (%FS<30%) were also excluded. BMIPP uptake scores as the ratio of heart/mediastinum (H/M) and liver/mediastinum (L/M) at 20 minutes after injection were analyzed and compared with clinical profile, serum parameters, and LV parameters obtained from echocardiography. Five of the 15 patients showed abnormal BMIPP images; two patients showed a decreased uptake in the inferior segments, while three showed a diffuse decrease in BMIPP uptake. Body mass index (BMI), fasting blood sugar (FBS), HbAIC, IRI, and LV end-diastolic diameter (LVEDD) were higher in these five patients with abnormal BMIPP findings (abnormal BMIPP group vs normal BMIPP group, BMI: 29 vs 23 kg/m2, p< 0.05; FBS; 178 vs 114 mg/dl, p<0.01; HbAIC; 7.6 vs 6.2%, p<0.01; IRI: 18.5 vs 9.5 μU/ml, p< 0.01; LVEDD: 52 vs 44 mm, p<0.05). 123I-metaiodobenzyl-guanidine (MIBG) scintigraphy in the five patients with abnormal BMIPP uptake showed more severe defects than in the 10 patients with normal BMIPP imaging. BMIPP scintigraphy demonstrated a significant correlation between H/M and L/M by BMIPP (r = 0.74, p<0.01). Furthermore, correlation between H/M by BMIPP scintigraphy and clinical parameters (BMI, systolic blood pressure, FBS, HbAIC, IRI) were found, suggesting that diabetes mellitus patients without over coronary heart disease show abnormal BMIPP imaging when their general glucose utility and 123I-MIBG uptake are severely impaired (progression of insulin resistance and sympathetic nerve involvement). BMIPP scintigraphy may be useful in investigating the pathogenesis and subclinical abnormality of diabetic heart.

AB - Fatty acid metabolism in the myocardium is affected by metabolic disorders such as diabetes mellitus. We evaluated 123I-,β-methyl-iodophenyl- pentadecanoic acid (BMIPP) myocardial scintigraphy in 15 diabetes mellitus patients without overt coronary heart disease. Patients with overt coronary heart disease were excluded by careful history taking, resting electrocardiography, treadmill exercise testing, echocardiography and resting 201TI scintigraphy. Patients with remarkably impaired left ventricular (LV) systolic function (%FS<30%) were also excluded. BMIPP uptake scores as the ratio of heart/mediastinum (H/M) and liver/mediastinum (L/M) at 20 minutes after injection were analyzed and compared with clinical profile, serum parameters, and LV parameters obtained from echocardiography. Five of the 15 patients showed abnormal BMIPP images; two patients showed a decreased uptake in the inferior segments, while three showed a diffuse decrease in BMIPP uptake. Body mass index (BMI), fasting blood sugar (FBS), HbAIC, IRI, and LV end-diastolic diameter (LVEDD) were higher in these five patients with abnormal BMIPP findings (abnormal BMIPP group vs normal BMIPP group, BMI: 29 vs 23 kg/m2, p< 0.05; FBS; 178 vs 114 mg/dl, p<0.01; HbAIC; 7.6 vs 6.2%, p<0.01; IRI: 18.5 vs 9.5 μU/ml, p< 0.01; LVEDD: 52 vs 44 mm, p<0.05). 123I-metaiodobenzyl-guanidine (MIBG) scintigraphy in the five patients with abnormal BMIPP uptake showed more severe defects than in the 10 patients with normal BMIPP imaging. BMIPP scintigraphy demonstrated a significant correlation between H/M and L/M by BMIPP (r = 0.74, p<0.01). Furthermore, correlation between H/M by BMIPP scintigraphy and clinical parameters (BMI, systolic blood pressure, FBS, HbAIC, IRI) were found, suggesting that diabetes mellitus patients without over coronary heart disease show abnormal BMIPP imaging when their general glucose utility and 123I-MIBG uptake are severely impaired (progression of insulin resistance and sympathetic nerve involvement). BMIPP scintigraphy may be useful in investigating the pathogenesis and subclinical abnormality of diabetic heart.

KW - I-MIBG)

KW - diabetes mellitus

KW - fatty acid (metabolism)

KW - glucose (metabolism)

KW - radioisotopes (I-BMIPP

UR - http://www.scopus.com/inward/record.url?scp=0028990752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028990752&partnerID=8YFLogxK

M3 - Article

C2 - 7666341

AN - SCOPUS:0028990752

VL - 26

SP - 23

EP - 32

JO - Journal of cardiography. Supplement

JF - Journal of cardiography. Supplement

SN - 0914-5087

IS - 1

ER -